Advances in the development of universal influenza vaccines

Influenza and other Respiratory Viruses

Volumn 7, Issue 5, 2013, Pages 750-758

  Gilbert, Sarah C ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Clinical; Influenza; Vaccine

Indexed keywords

ANTIBODY; DNA VACCINE; IMMUNOGLOBULIN G ANTIBODY; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; M2E ANTIBODY; MATRIX PROTEIN 1; NEUTRALIZING ANTIBODY; NUCLEOPROTEIN; PROTEIN M2; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS PROTEIN; VIRUS VECTOR;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY TITER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMPLEMENT DEPENDENT CYTOTOXICITY; DNA IMMUNIZATION; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSPOT ASSAY; EXPERIMENTAL MODEL; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; INFLUENZA VIRUS C; MAJOR HISTOCOMPATIBILITY COMPLEX; MORTALITY; NONHUMAN; PANDEMIC INFLUENZA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTECTION; REVIEW; SEASONAL INFLUENZA; T LYMPHOCYTE; VIRION; VIRUS MORPHOGENESIS; VIRUS SHEDDING; VIRUS TRANSMISSION;

CLINICAL; INFLUENZA; VACCINE;

ANIMALS; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; PUBLIC HEALTH;

EID: 84882628111     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/irv.12013     Document Type: Review

References (57)

1. de Jong JC, Beyer WE, Palache AM, Rimmelzwaan GF, Osterhaus AD. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol 2000; 61:94-99.
2. Bodewes R, Rimmelzwaan GF, Osterhaus AD. Animal models for the preclinical evaluation of candidate influenza vaccines. Expert Rev Vaccines 2010; 9:59-72.
3. Vergara-Alert J, Argilaguet JM, Busquets N et al. Conserved synthetic peptides from the hemagglutinin of influenza viruses induce broad humoral and T-cell responses in a pig model. PLoS ONE 2012; 7:e40524.
4. Brown IH. The epidemiology and evolution of influenza viruses in pigs. Vet Microbiol 2000; 74:29-46.
5. Lefevre EA, Carr BV, Inman CF et al. Immune responses in pigs vaccinated with adjuvanted and non-adjuvanted A(H1N1)pdm/09 influenza vaccines used in human immunization programmes. PLoS ONE 2012; 7:e32400.
6. Waddington CS, Walker WT, Oeser C et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6months-12years: open label, randomised, parallel group, multicentre study. BMJ 2010; 340:c2649.
7. Ebrahimi SM, Tebianian M. Influenza A viruses: why focusing on M2e-based universal vaccines. Virus Genes 2011; 42:1-8.
8. Slepushkin VA, Katz JM, Black RA, Gamble WC, Rota PA, Cox NJ. Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine 1995; 13:1399-1402.
9. Huleatt JW, Nakaar V, Desai P et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008; 26:201-214.
10. Wolf AI, Mozdzanowska K, Williams KL et al. Vaccination with M2e-based multiple antigenic peptides: characterization of the B cell response and protection efficacy in inbred and outbred mice. PLoS ONE 2011; 6:e28445.
11. Zhou C, Zhou L, Chen YH. Immunization with high epitope density of M2e derived from 2009 pandemic H1N1 elicits protective immunity in mice. Vaccine 2012; 30:3463-3469.
12. Heinen PP, Rijsewijk FA, de Boer-Luijtze EA, Bianchi AT. Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus. J Gen Virol 2002; 83(Pt 8):1851-1859.
13. Kitikoon P, Vincent AL, Janke BH et al. Swine influenza matrix 2 (M2) protein contributes to protection against infection with different H1 swine influenza virus (SIV) isolates. Vaccine 2009; 28:523-531.
14. Turley CB, Rupp RE, Johnson C et al. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 2011; 29:5145-5152.
15. Table for pandemic and potentially pandemic influenza vaccines [database on the Internet], 2012. Available at http://www.who.int/vaccine_research/diseases/influenza/flu_trials_tables/en/index.html (Accessed 14 May 2012).
16. Tekamp PA, Penhoet EE. Quantification of influenza virus messenger RNAs. J Gen Virol 1980; 47:449-459.
17. Epstein SL. Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. J Infect Dis 2006; 193:49-53.
18. Mathews JD, McBryde ES, McVernon J, Pallaghy PK, McCaw JM. Prior immunity helps to explain wave-like behaviour of pandemic influenza in 1918-9. BMC Infect Dis 2010; 10:128.
19. Cowling BJ, Ng S, Ma ES et al. Protective efficacy of seasonal influenza vaccination against seasonal and pandemic influenza virus infection during 2009 in Hong Kong. Clin Infect Dis 2010; 51:1370-1379.
20. McMichael AJ, Gotch FM, Noble GR, Beare PA. Cytotoxic T-cell immunity to influenza. N Engl J Med 1983; 309:13-17.
21. Brett IC, Johansson BE. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system. Virology 2005; 339:273-280.
22. Wilkinson TM, Li CK, Chui CS et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 2012; 18:274-280.
23. Bevan MJ. Helping the CD8(+) T-cell response. Nat Rev Immunol 2004; 4:595-602.
24. Nakanishi Y, Lu B, Gerard C, Iwasaki A. CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature 2009; 462:510-513.
25. McMichael AJ, Gotch F, Cullen P, Askonas B, Webster RG. The human cytotoxic T cell response to influenza A vaccination. Clin Exp Immunol 1981; 43:276-284.
26. McMichael AJ, Gotch FM, Dongworth DW, Clark A, Potter CW. Declining T-cell immunity to influenza, 1977-82. Lancet 1983; 2:762-764.
27. Lee LY, Ha do LA, Simmons C et al. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest 2008; 118:3478-3490.
28. Gilbert SC. T cell-inducing vaccines - what's the future. Immunology 2012; 135:19-26.
29. Bejon P, Peshu N, Gilbert SC et al. Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya. Clin Infect Dis 2006; 42:1102-1110.
30. Berthoud TK, Hamill M, Lillie PJ et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis 2011; 52:1-7.
31. Lillie PJ, Berthoud TK, Powell TJ et al. A preliminary assessment of the efficacy of a T cell-based influenza vaccine, MVA-NP+M1, in humans. Clin Infect Dis 2012; 55:19-25.
32. Smith LR, Wloch MK, Ye M et al. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine 2010; 28:2565-2572.
33. Atsmon J, Kate-Ilovitz E, Shaikevich D et al. Safety and immunogenicity of multimeric-001 - a novel universal influenza vaccine. J Clin Immunol 2012; 32:595-603.
34. Stoloff GA, Caparros-Wanderley W. Synthetic multi-epitope peptides identified in silico induce protective immunity against multiple influenza serotypes. Eur J Immunol 2007; 37:2441-2449.
35. Pleguezuelos O, Robinson S, Stoloff GA, Caparros-Wanderley W. Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled Phase I trial. Vaccine 2012; 30:4655-4660.
36. Ekiert DC, Bhabha G, Elsliger MA et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009; 324:246-251.
37. Ekiert DC, Friesen RH, Bhabha G et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 2011; 333:843-850.
38. Corti D, Voss J, Gamblin SJ et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011; 333:850-856.
39. Wrammert J, Koutsonanos D, Li GM et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 2011; 208:181-193.
40. Nabel GJ, Fauci AS. Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat Med 2010; 16:1389-1391.
41. Wei CJ, Boyington JC, McTamney PM et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 2010; 329:1060-1064.
42. Steel J, Lowen AC, Wang TT et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 2010; 1:e00018-10.
43. Bommakanti G, Citron MP, Hepler RW et al. Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc Nat Acad Sci USA 2010; 107:13701-13706.
44. Ledgerwood JE, Wei CJ, Hu Z et al. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis 2011; 11:916-924.
45. Krause JC, Tsibane T, Tumpey TM, Huffman CJ, Basler CF, Crowe JE Jr. A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. J Virol 2011; 85:10905-10908.
46. Galli G, Medini D, Borgogni E et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci USA 2009; 106:3877-3882.
47. Kreijtz JH, Suezer Y, de Mutsert G et al. Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques. J Infect Dis 2009; 199:405-413.
48. Arinaminpathy N, Ratmann O, Koelle K et al. Impact of cross-protective vaccines on epidemiological and evolutionary dynamics of influenza. Proc Nat Acad Sci USA 2012; 109:3173-3177.
49. Ambrose CS, Wu X, Knuf M, Wutzler P. The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17years of age: a meta-analysis of 8 randomized controlled studies. Vaccine 2012; 30:886-892.
50. LaRussa P. Pandemic novel 2009 H1N1 influenza: what have we learned? Semin Respir Crit Care Med 2011; 32:393-399.
51. Simonsen L. Available evidence points to low effectiveness of influenza vaccines for older people. Evid Based Med 2010; 15:109-110.
52. Bodewes R, Fraaij PL, Geelhoed-Mieras MM et al. Annual vaccination against influenza virus hampers development of virus-specific CD8 T cell immunity in children. J Virol 2011; 85:11995-12000.
53. Bodewes R, Kreijtz JH, Baas C et al. Vaccination against human influenza A/H3N2 virus prevents the induction of heterosubtypic immunity against lethal infection with avian influenza A/H5N1 virus. PLoS ONE 2009; 4:e5538.
54. Bodewes R, Kreijtz JH, Geelhoed-Mieras MM et al. Vaccination against seasonal influenza A/H3N2 virus reduces the induction of heterosubtypic immunity against influenza A/H5N1 virus infection in ferrets. J Virol 2011; 85:2695-2702.
55. Bodewes R, Kreijtz JH, Hillaire ML et al. Vaccination with whole inactivated virus vaccine affects the induction of heterosubtypic immunity against influenza virus A/H5N1 and immunodominance of virus-specific CD8+ T-cell responses in mice. J Gen Virol 2010; 91(Pt 7):1743-1753.
56. Benowitz I, Esposito DB, Gracey KD, Shapiro ED, Vazquez M. Influenza vaccine given to pregnant women reduces hospitalization due to influenza in their infants. Clin Infect Dis 2010; 51:1355-1361.
57. Osterhaus AD, Rimmelzwaan GF, Martina BE, Bestebroer TM, Fouchier RA. Influenza B virus in seals. Science 2000; 288:1051-1053.